Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon
- PMID: 2416265
- DOI: 10.1002/ana.410180404
Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon
Abstract
A battery of immunological functions was studied over a 2-year period in conjunction with a placebo-controlled trial of natural human alpha interferon in patients with multiple sclerosis. IgG synthesis was increased both systemically and intrathecally by administration of interferon; however, there were only minor changes in cerebrospinal fluid oligoclonal bands. Levels of helper and suppressor T lymphocytes fluctuated independently of clinical exacerbations, although mean helper/suppressor ratios were higher in multiple sclerosis patients than in controls and increased further during interferon treatment. Cerebrospinal fluid myelin basic protein and antibodies to basic protein were not affected by exacerbations or by interferon administration. Circulating IgG antibodies induced by interferon treatment appeared to be directed at a non-interferon contaminant of the preparation. None of the assays was a consistent indicator of disease activity or of clinical response to interferon.
Similar articles
-
Oligoclonal immunoglobulins and immunoreactive myelin basic protein in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases.Acta Neurol (Napoli). 1985 Jun-Aug;7(3-4):311-4. Acta Neurol (Napoli). 1985. PMID: 2414977 No abstract available.
-
Prognostic value of cerebrospinal fluid electrophoresis in optic neuritis and suspected multiple sclerosis.Ital J Neurol Sci. 1987 Jun;Suppl 6:77-80. Ital J Neurol Sci. 1987. PMID: 3654181
-
The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis.Ann Neurol. 1985 May;17(5):475-80. doi: 10.1002/ana.410170510. Ann Neurol. 1985. PMID: 2408558
-
Oligoclonal bands and antibody responses in multiple sclerosis.J Neurol. 2002 Apr;249(4):375-89. doi: 10.1007/s004150200026. J Neurol. 2002. PMID: 11967640 Review.
-
The significance of abnormal immune responses in patients with multiple sclerosis.J Neuroimmunol. 1981 Jun;1(2):141-72. doi: 10.1016/0165-5728(81)90040-0. J Neuroimmunol. 1981. PMID: 6461670 Review.
Cited by
-
Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings.J Neurol. 1988 Jan;235(3):171-3. doi: 10.1007/BF00314311. J Neurol. 1988. PMID: 3367166
-
Mechanisms of action of interferon-beta in multiple sclerosis.Springer Semin Immunopathol. 1996;18(1):125-48. doi: 10.1007/BF00792613. Springer Semin Immunopathol. 1996. PMID: 8984676 Review. No abstract available.
-
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity.Cytokine Growth Factor Rev. 2021 Apr;58:134-140. doi: 10.1016/j.cytogfr.2021.01.004. Epub 2021 Jan 29. Cytokine Growth Factor Rev. 2021. PMID: 33563543 Free PMC article. Review.
-
Intraventricular interferon in a case of subacute sclerosing panencephalitis.Ital J Neurol Sci. 1987 Jun;8(3):277-81. doi: 10.1007/BF02337487. Ital J Neurol Sci. 1987. PMID: 2442118
-
The effect of interferon-alpha on the ecto 5'-nucleotidase of human lymphoblastoid B-cell lines depends on the class of immunoglobulin secreted.Immunology. 1991 Sep;74(1):44-9. Immunology. 1991. PMID: 1937572 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical